Skye Bioscience Earnings Call Transcripts
Fiscal Year 2025
-
Nimacimab showed additive, durable weight loss and favorable safety in combination with GLP-1s, prompting higher dose studies and subcutaneous formulation work. Cash runway extends through Q4 2026, with key clinical and regulatory milestones expected in the coming year.
-
A peripherally restricted CB1 antibody shows promise for obesity, with strong safety and synergistic weight loss when combined with incretins. Ongoing studies focus on higher dosing, durability, and optimal combinations, supported by robust preclinical and clinical data.
-
Phase II data for a peripherally restricted CB1 antibody showed suboptimal monotherapy efficacy but strong synergy with semaglutide, leading to 30% greater weight loss at 26 weeks. Higher dosing and improved formulations are planned, with key 52-week extension data expected in Q1.
-
Q3 2025 saw increased R&D investment and strong progress in nimacimab's clinical development, with combination data showing significant added weight loss and durability versus semaglutide alone. Cash reserves are expected to fund operations into 2027, and no new safety concerns have emerged.
-
The phase 2a CBeyond trial found that nimacimab monotherapy at 200 mg did not meet its primary endpoint, but its combination with semaglutide produced clinically meaningful, additive weight loss and improved body composition without added safety concerns. PK analysis indicated underexposure at the tested dose, supporting future studies with higher dosing.
-
A novel CB1 antibody for obesity is advancing through phase 2a, with top-line data expected late Q3 or early Q4 2024. The program targets unmet needs in weight loss, maintenance, and combination therapy, with strong safety and preclinical efficacy. Cash runway extends to Q1 2027.
-
Expert panel reviewed nimacimab’s preclinical and clinical progress, highlighting its potential for durable, additive weight loss, superior tolerability, and minimal neuropsychiatric risk. KOLs emphasized the importance of GI tolerability, lean mass preservation, and maintenance benefits for long-term success.
-
Nimacimab's Phase IIa trial is progressing ahead of schedule, with top-line data expected late Q3/early Q4 2025. Financially, cash reserves of $48.6M support operations through Q1 2027, and R&D expenses rose due to manufacturing and clinical activities.
-
Nemesimab, a first-in-class CB1 antibody, aims to address the unmet need in obesity by offering a safer, durable alternative to incretin therapies. Preclinical and early combination data show promising efficacy and safety, with pivotal phase II results expected later this year.
-
Phase IIA CBION trial enrollment completed ahead of schedule and extended to 52 weeks, with top-line 26-week data expected in late Q3 or early Q4 2025. Preclinical data show nimacimab's strong efficacy and safety profile, supporting large commercial potential as both monotherapy and in combination with GLP-1.
-
A novel CB1 inhibitor is being developed for obesity, focusing on peripheral fat metabolism to avoid neuropsychiatric risks. A four-arm phase II trial is underway, with top-line data expected late Q3 to early Q4, and a cash runway through Q1 2027.
-
Nimacimab, a peripherally restricted CB1-inhibiting antibody, is positioned to address unmet needs in obesity treatment by offering improved tolerability, preservation of lean mass, and complementary action to GLP-1s. Phase IIa data are expected in 2024.
-
Obesity and metabolic diseases are increasingly treated as chronic conditions, with new therapies like peripherally restricted CB1 inhibitors offering potential for sustainable weight loss and improved metabolic health. Nimacimab is advancing through Phase 2 trials, targeting unmet needs in tolerability and efficacy, with key data expected in 2025.
-
Obesity and metabolic diseases are being redefined as chronic conditions needing innovative therapies. Nimacimab, a peripherally restricted CB1 inhibitor antibody, shows promise for safe, sustainable weight loss, with Phase II data expected in 2025 and a strong financial position supporting development.
Fiscal Year 2024
-
Accelerated Nimacimab trial enrollment enables earlier data readout, with robust financial backing and a strategic focus on obesity. Cash reserves support operations through Q1 2027, while manufacturing and regulatory preparations advance. Strong industry interest in non-GLP-1 mechanisms underpins market opportunity.
-
CB1 inhibition is a validated target for obesity, but safety concerns with central nervous system exposure have limited small molecule approaches. Nimacimab, a peripherally restricted CB1 antibody, shows promising preclinical efficacy and safety, with a robust phase II trial underway and interim data expected in 2025.
-
A differentiated CB1 inhibitor pipeline is advancing, with nimacimab in Phase 2 targeting obesity through peripheral mechanisms to avoid central side effects. Interim clinical data in Q2 2025 will focus on safety and weight loss, with a strong financial runway supporting development.
-
Nimacimab, a peripherally restricted CB1 antibody, is in phase 2 for obesity, aiming for 8% weight loss and lean mass preservation, with interim data expected in Q2 2025. The program targets gaps left by GLP-1s, with robust safety and market differentiation.
-
Nimacimab, a peripherally restricted CB1 antibody, is in phase II for obesity, aiming to deliver robust weight loss with a strong safety profile and minimal CNS side effects. The program explores both monotherapy and combination with GLP-1s, with pivotal data and strategic decisions expected in 2025.
-
Nimacimab, a peripherally restricted CB1 inhibitor, is advancing through a well-enrolled phase 2 obesity trial, with new preclinical data supporting its efficacy and safety profile. Strong financials provide a multi-year runway, and the company is expanding its metabolic health pipeline.